| (Values in U.S. Thousands) | Dec, 2023 | Dec, 2022 | Dec, 2021 | Dec, 2020 | Dec, 2019 |
| Sales | 80 | 1,030 | 1,140 | 0 | 0 |
| Sales Growth | -92.23% | -9.65% | unch | unch | unch |
| Net Income | -48,820 | -33,020 | -24,770 | -22,220 | -21,900 |
| Net Income Growth | -47.85% | -33.31% | -11.48% | -1.46% | +7.40% |
Actinium Pharmaceuticals Inc (ATNM)
1.5200 +0.0300 (+2.01%) 04/02/25 [NYSE Arca]
1.4700 x 1 1.6100 x 12
Realtime by (Cboe BZX)
1.4700 x 1 1.6100 x 12
Realtime 1.5200 unch (unch) 16:20 ET
for Wed, Apr 2nd, 2025
Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing ARCs or Antibody Radiation-Conjugates, which combine the targeting ability of antibodies with the cell killing ability of radiation. Actinium's lead application for their ARCs is targeted conditioning, which is intended to selectively deplete a patient's disease or cancer cells and certain immune cells prior to a BMT or Bone Marrow Transplant, Gene Therapy or Adoptive Cell Therapy (ACT) such as CAR-T to enable engraftment of these transplanted cells with minimal toxicities. With their ARC approach, they seek to improve patient outcomes and access to these potentially curative treatments by eliminating or reducing the non-targeted chemotherapy that is used for conditioning in standard practice currently. Their lead product candidate, I-131 apamistamab (Iomab-B) is being studied in the ongoing pivotal Phase 3 Study of Iomab-B in Elderly Relapsed or Refractory Acute Myeloid Leukemia (SIERRA) trial for BMT conditioning. The SI
Fiscal Year End Date: 12/31